The 10 Most Emerging Biotech Companies To Watch in 2022 Octomber2022

Jeff Aronin, Chairman Evozyne

The cure to life is Biotechnology

Way to save the life of every individual.

Embarking on the Prospects to Foster Bio-Innovations

Editor’s Desk

AbhishekJoshi AbhishekJoshi

iotechnologyhasbecomeamajorenginefor

Bnationalandurbancompetitivenessinthetwentyfirstcentury.Biotechnologyisbeingexploredasa crucialdevelopmentforfutureadvancementsandgrowing competitionforpolicymakers.

Ithasalwaysbeenaknowledge-drivensectorbecauseofits consistencyincomprehensivelyworkingtocreatevalue, decodinggenomicsandproteomicsandbeinga paradigmaticknowledge-basedeconomicactivity. Biotechnologyindustriesarealsoamongthemost innovativeandimportanteconomicdriversinthemodern businessworld.

However,thebiotechnologymarkethasraisedexpectations amonginvestors,workers,andconsumers.Thisispartly relatedtotheCOVID-19pandemic,whichmotivatedthe accelerationininvestmentsinthesectorsocommonly characterizedbyitslong-termresults.Biotechindustry trendshaverevolvedarounddiversifyingtheproductionof patentsandinvestingalotofcapitalwithoutexpecting shortandmid-termresults—atypicalscriptregardingthe sectorthatcouldholdontoinvestors.

Eventually,thisrequiresconsideringhowtheycanscaleup andwhatisrequired,inordertodeliverontheirpromiseof providinginnovativemedicinestopatients.Earlyinthelife cycle,abiotechcompany'smanagementteamtypically growsthebusinessthroughafewcoreassetsandlimited programmers,focusingitsresourceswherethemostvalue canbegained,suchasdifferentiationinmanufacturing, understandingofdiseaseandbiology,ordrugchemistry

Oneoftheimportantaspectsthathavebeensignificantly contributingtocoredriversoflonger-termsuccessis buildingaportfolioofproductstosustaingrowth–this researchseekstoidentifywhichportfolioapproacheshave

enabledbiotechtoscaleitsprogress,stimulateinnovation forpatientsandcreatedfinancialsuccessforinvestorsand founders.

Tofurthersucceedintheniche,emergingcompaniestryto createan"end-to-end"entityfromresearchand developmenttocommercialization,bringingtheir product(s)tomarketthemselves.Moreover,ensuringthe R&Dprofilecontinuestobethefocusofmostotherbiotech companies'attentionremainsaprimaryaimforthese biotechcompanies.

AmongthosewhoareR&D-focused,someadopta "diversifyapproach,"resultinginasignificantincreasein thenumberofassetsacrossmultipletherapeuticareasand relyingheavilyonrevenuegeneratedthroughcollaboration agreementstoadvanceassetspastpre-clinicalandPhase1 stages.

Embracingtheascendingodysseyofthestarletsthatare enablingtransformationsinthebiotechindustry,Insights Successfeaturesthetriumphtrailof"The 10 Most Emerging Biotech Companies to Watch in 2022 ”

Flipthroughthepagesandreadontocomprehendthe immersiveadvancementsthatarebeingdrivenbyavision toempowerlimitlessennoblementsintheglobalhealthcare industry.

Have a Delightful Read!

CompanyName

3Scan 3scan.com

ClinCapturec lincapture.com

CMICInc en.cmicgroup.com

Most Emerging Biotech

The 10 Companies To Watch in 2022

FeaturedPerson

ToddHulman, CEO&Co-founder

ScottWeidley, President&CEO

JennyLin, COO&BoardofDirector

JeffAronin, Chairman Evozyne evozyne.com

GoldenHelixh goldenhelix.com

AndreasScherer, President&CEO

JimKaskade, CEO Janrain janrain.com

Metrendalytics metrendalytics.com

PeachtreeBioResearch Solutions peachtreebrs.com

JanMiotto, President

SharonHilton, COO &KristyNichols, CEO

RoyFarfara, Founder&CTOTrioxNano

Brief

3Scanisturningtissuebiologyandhistopathologyintodata science,givingresearcherstheinsightstheyneedtobreaknew ground.

ClinCaptureisrevolutionizingtheclinicaltrialindustrywith VirtualDataCapture®andistheonlyproviderofVDC®,a leading-edgesuiteofproductsdesignedtoexpediteremoteand decentralizedclinicaltrials.

CMICisaninnovativeanduniqueproviderofhigh-quality solutionsforthehealthcareindustry. Wecreatevaluebyacceleratingtheaccesstotherapiesthat improvepatients’lives.

Evozynecombinesevolutionanddeeplearningtechnologyto createhighlyfunctionalnovelproteins—NaturalMachines™ —tosolvelongstandingchallengesintherapeuticsand sustainability

GoldenHelixhasbeendeliveringindustry-leading bioinformaticssolutionsforover20yearswith1,000sofusers aroundtheworld.

Janrainisthefirstchoiceofglobalenterprisesformissioncriticalcustomeridentityandaccessmanagement(CIAM) needs.

MetrendalyticsConsulting,focusedonhelpingcompanies develophighlycustomizedandflexiblebusinessintelligence solutions.

Theorganizationaimstodeliverexcellentclinicaldevelopment servicesandinnovativeresourcingsolutionsthatletourclients completetheirclinicaltrialsinanefficientandcost-effective manner

TrioxNanoLtd(Israel)isaninnovativebio-technology companydevelopingprogrammablebiologicnanocarriersthat areabletoaccuratelydeliverpayloadstotheirtarget.

C o v e r S t o r y

Engineering Biology to Solve Societal Challenges

If nature is the world's best engineer, imagine what it can do if it's fast-forwarded by a few million years.

Evozyne -Jeff Aronin, Chairman, Evozyne

echnicaladvancementsingeneticsand

Tsupercomputingaredrivinganastonishingamount ofscientificprogress,colloquiallyknownasthe biologyrevolution.Theadvancescomeatafortuitoustime. Environmentalthreatsarechippingawayatthequalityof lifeformillions,whilenewviralillnessescontinueto emergeandthousandsofknowndiseaseslackeffective treatments.

Evozyne,foundedbyParagonBiosciences,wascreated onthepremisethatthenew-foundabilitytocreatehighperformanceproteinscandeliversolutionstothesomeof mostintractablemodernproblems. Thecompanybelieves thatbylearningfromevolution,itispossibletoengineer future-proofedinterventionsforpatientsandaddress environmentalchallengesincarboncaptureandenergy storage.

Tolearnmoreaboutitsbiology-basedadvancements,weat InsightsSuccesscrossedpathswithEvozyne'steam,andin thefollowinginterview,thecompanyoutlinesits pathbreakingvisiontobenefithumanity

Below are the highlights of the interview. Whatwastheinitialideabehindtheinceptionof Evozyne?

EvozynewasfoundedbyParagonBiosciencestoadvance boundary-breakingbiologyfromthelaboratoryandintothe realworld,whereitcansolvecomplexproblems. Believingthattheengineeredproteinswilldramatically acceleratescientificbreakthroughs,intwoyearswe recruitedaworld-classteamofnearly100computational scientists,researchers,andcommercialleaderstoconducta seriesofvalidationprojectsfromEvozyne'snew30,000square-footlabinChicago.

Evozyne'sevolution-baseddesignisaboutencapsulating vitalinformationfromtheevolutionaryhistoryofaprotein intoacomputationallydefinedlatentspacethatenables rationaldesignofnatural-likeproteins.Whencombined withaniterativedesign-build-testapproach,themodels generateproteindesignsthatfarexceedperformanceof naturalproteinsandcanbedeployedininreal-world applications.

Inanearlyproject,EvozynepartneredwithTakeda,the Japanesepharmaceuticalcompany,toimprovethe therapeuticpotentialofaspecifictargettotreatasevere geneticdisease.Thisinheriteddisordercausesadangerous

build-upofphenylalaninewhenapersoneatsproteinor foodscontainingaspartame,whichseverelyalterstheir qualityoflife.

Evozynedeliveredanengineeredenzymethatgreatly exceededTakeda'sdesignspecifications,whichledtoan initialmulti-assetlicensingagreementworthupto$400 millionpluspotentialroyaltiesfromanycommercial productresultingfromthecollaboration.Ourtechnology outperformedexpectationsinthiscriticaltestandresulted inanimportantcollaborationforbothcompanies.Weare hopefulthispartnershipwithTakedawillleadtonew treatmentsthatsignificantlyimprovethequalityoflifefor patients.

Whataretheprimaryobjectivesandphilosophyof Evozyne?

Webelieveboundary-breakingbiologyisthekeyto transformationalapplicationsintherapeuticsand sustainability.Understandingthatnatureistheoriginaland bestengineer,weusedeepevolutionarylearninginthelab tounderstandmillionsofyearsofevolution.

Byusingevolution-baseddesign,we'reabletotacklesome ofsociety'sbiggestchallenges,likefindingtreatmentsfor patientswithuntreateddiseasesanddevelopingsolutions forsustainabilityconcerns.

Philosophically,wearehighlypragmaticandourdesignbuild-testapproachisappliedtoeveryaspectofourwork. Wepartnerwithlike-mindedentities,workingtogetherto findworld-changingsolutions.

Torealizetheimpactandpotentialofourengineered proteins,weneedpartnerswhoshareourvisionforabetter worldandacommitmenttothebreakthroughapproaches requiredtogetthere.Ournext-generationproteinscanbe tailoredacrossfunctions,andourefficientdesign-build-test cyclesenablecommercial-scalesolutionsthatunlocknew productsandIPforourpartners.

Whatareyourkeyofferingsthathaveafootholdinthe industry?

Evozynebeganbycombiningartificialintelligence, specificallymachinelearning,withappliedbiologyto acceleratescientificdiscovery.Theprocessspeedsuplead identificationfornewmedicines,whichcanresultin findingsthatsupportinvestigationalnewdrugapplications andbiologiclicenseapplicationsforexperimental

The 10 Most Emerging Biotech Companies To Watch in 2022

therapeutics.Fromatimelinepointof view,Evozyneworksfromtheearliestpoints, identifyingandoptimizingleadtargets,andcontinuesits workthroughdevelopingexperimentaltherapeuticsand supportingthemthroughPhase3clinicaltrials.

Currently,wearecreatinghigh-performanceenzymesfor ourpartnersatTakedaanddevelopingantibody,gene optimization,andCRISPRtechnologyplatformsthatwe believewillleadtothedevelopmentofbreakthrough therapeuticsforpatients.

Onthesustainabilityside,proteinengineeringmovesthe sciencebeyondtraditionalchemicalcatalystsbydeveloping enzymesthatcanwithstandindustrialconditions, functioninginhigh-temperatureconditions,and overcomingpHresistance.

Ourleadsustainabilitycandidateisengineeredtoperform attemperaturesabove260degreesFahrenheitinan industrialsetting.Untilnow,noenzymehasbeenableto

functioninthe conditions associatedwithpowergeneration.

Ourtestsindicatethatwehaveaproductthatmeetsthe challengeofenzymaticon-sitecarboncapture,which meansifsuccessfultheCO frompowergenerationisnever2 releasedintotheatmosphere.Welookforwardtoproving itsperformance,firstattheUniversityofKentuckythisyear andlaterattheNationalCarbonCaptureCenterin Alabama.

WhataretheroadblocksthatEvozynefacesintheeverchanginglandscapeofthebusinessworld?

Scienceisunpredictable,andit'shard.Thosetwofacts,plus thecompetitivenatureofbiotechbusinesses,makeit temptingtorushproductstomarket.Therearenotable examplesofsyntheticbiologycompaniesthatgaveinto thattemptation,soldproductsthatdidn'tperformasbilled andsubsequentlyfailed.

Evozynefollowedthosestoriesclosely,andourteamis committedtodoingthingsdifferently.Ourhighly pragmatic,design/built/testmodelrequiresustorepeatedly provetoourselves,withobjectivedata,thatthetechnology performsasexpectedinreal-worldconditions.Evozyne willbringproductstomarketwhenandiftheyareproven toahighlevelofcertainty

Beingfirstcanbeadisadvantageifyoufailtomeetmarket expectations.Protectingourreputationisatoppriorityfor Evozyne,andthatmeansmakingsurewe'vedonethehard worktoprovetheperformanceofourtechnologyplatforms.

Beyondreputationmanagement,recruitingtopscientific talentisahurdleformanybiotechcompanies.Fortunately, Evozynehasprovenitsabilitytohiretoptalent,whichwe attributetoourpragmaticapproach,theimpactofthe problemswe'reworkingtosolve,andthefinancialhealthof ourcompany.IthelpsthatChicagoisaworld-classcity, withgloballyrenowneduniversitiesandathriving ecosystemthatsupportsemergingbiotechandpharma companies.Thescientifictalentweneedtosucceedwants toworkhereand,more important,ishappy livinghere.

Howisyourcompanyadaptingtomarketorientation?

Nearlyhalfoftheworld'sdiseaseburdenwillbeaddressed bybiologyinthenext20years.Withthatinmind,we're pursuinglife-changingtreatmentsforpatientsandfinding waystoimprovelifeforpatientswithdiseasesthataren't currentlytreatable.Therearemorethan10,000diseasesfor whichnomedicineexists,andwehopetobepartofthe solutionforpatientswholackoptions.

Onthesustainabilityside,we'reworkingtoaddressclimate changewithanon-sitesolutionforcarboncapture.We're uncoveringnewpathstoreplaceharmfulplasticsand addressingglobalwarmingbymakingcarboncapturea reality.Ourgoalistobuildhigh-performanceproteins,with exceptionallyadvancedfunctionalitythatmakeswhat's possibleareality.Theyaredesignedtobeconsistentwith thelawsofnatureandmatchthecomplexcharacterof naturalenvironments,enablingbiology-basedsolutionsthat openourimaginationtowhat'spossibleinsolvingsomeof society'smostintractableproblems.

Whatisyourapproachtoimplementinginnovative technologies?

It'simportanttounderstand thattheproteinsequence

spaceisimpossiblylarge—muchlargerthanthenumberof atomsintheknownuniverse—andnoexistingapproach cancomprehensivelysearchit.

Yetthat'swherewebelievewe'llfindanswerstotheworld's mostpressingscientificquestions.

Ourmachinelearningmodelshelpusfindevolvable proteinsfromthatvastspacethatcanbeengineeredtomeet realworldchallenges.Moreimportantly,welearnfrom everysequencegeneratedinthedesignprocess,notjust fromtheonesthatwork.

Evozynegeneratesgenotype-phenotypemappingforevery sequencegenerated,addingtoourlibrariesandabilityto finddesiredsolutionsfaster.Thedesignrulesuncovered fromthesesequenceshelpussimultaneouslyoptimize severalproteinfunctions.That'sawholelotmoreefficient thanoptimizingonepropertyatatime.

Thisfunctionalinnovationformsourdesignphilosophy, unlockingthenaturalpotentialofevolvedproteins.

Howdoesyourcompanyprovideasocietalbenefit?

We'reusingsciencetosolvesomeofthemostcomplex problemsoursocietyfaces.

Thinkaboutitlikethis.Ourplatformiscapableofcreating moleculesthatsurpassthecurrentlimitsofperformance. Wecanachievetargetedimprovementsinfunctionthat mirrorsthecapabilitiesofnaturalevolution.Ifnatureisthe world'sbestengineer,imaginewhatitcandoifit'sfastforwardedbyafewmillionyears.

WhatisthenextchapterforEvozyne?

Ourfocusisondevelopingtechnologyplatformsfor therapeuticsandsustainability.Onthetherapeuticsside,the focusisongeneoptimization,geneediting,andfutureproofedantibodies.

Genereplacementtherapyrequiresbetter-than-wildtype performinggenestominimizedosing,maximizeefficacy, andreduceimmunogenicity.Existinggenetherapiesarenot simultaneouslyoptimizedacrossallthesedimensions. Furthermore,certaindiseasesrequirereplacementofgenes thataretoolargetofitintoexistingdeliverytechnologies, renderingtheminaccessible.

Usingourcomputationalbiologyapproach,weengineer transgeneswithsuperiorperformanceinactivity,affinity, stability,andimmunogenicity.Inaddition,Evozyne's technologyenablesminiaturizationofthegenecassette, unlockingcuresforpreviouslyinaccessiblediseases. GeneeditingwithCRISPR-Casnucleaseshasintroduced newtherapeuticmodalitiestotreatawiderangeofdiseases. Yettheexistingnucleasesarenotspecificenoughandcan causeoff-targetediting,whichmeanstheyeditthegenome inareasthatarenotintended.

Byaugmentingandredesigningthenucleasescreatedby nature,Evozyneisdevelopingacomprehensivelibraryof highlyspecificCasnucleasesthatcanaccessmostofthe genome.Thiscombinationofaccessibilityandspecificity willallowpreviouslyuntreatablediseasestobecuredsafely andeffectivelywithourenzymes.

ThePandemicprovidedanothercomplexproblemthatwe hopetosolve.Weallknowthatasvirusesmutate,they developresistancetoantibodies,renderingtherapeutics ineffective.Theproblemtreatingviralinfectionisoneof understandingtheevolvabilityofthevirus.Despite widespreadresearch,currentdiscoverytoolshavelimited successincounteringviralresistance.

Usingourabilitytounderstandtheconstraintsonviral evolution,Evozyneisdevelopinganapproachtogenerate future-proofed,broadlyneutralizingantibodies.Ourfirst applicationofthisplatformisavariant-resistantCOVID-19 antibody.

Evozyne'ssustainabilitypracticeisfocusedoncarbon captureandbatterytechnology.

Capturingcarbonatthepointofproductionhasbeen inefficientandenergy-intensive.Rightnow,it'stoo expensivetoreduceemissions.Whilenaturallyoccurring solutionscanimproveefficiency,theycannotwithstand harshindustrialconditionsandcan'tperformathigh temperatures.

Leveragingdesignrulesencodedbynature,Evozyneis developingahighlyefficientorganiccatalystthatremains stableintherequiredindustrialconditions,makingcarbon captureatthepointofproductioncost-effective.

The

Most Emerging Biotech Companies To

The 10 Most Emerging Biotech Companies To Watch in 2022

The 10 Most Emerging Biotech Companies To Watch in 2022

The 10 Most Emerging Biotech Companies To Watch in 2022

The 10 Most Emerging Biotech Companies To Watch in 2022

The 10 Most Emerging Biotech Companies To Watch in 2022

The 10 Most Emerging Biotech Companies To Watch in 2022